Home » Stocks » CGEM

Cullinan Management, Inc. (CGEM)

Stock Price: $33.88 USD -1.20 (-3.42%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
Market Cap 1.27B
Revenue (ttm) n/a
Net Income (ttm) -35.08M
Shares Out 39.50M
EPS (ttm) -0.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $33.88
Previous Close $35.08
Change ($) -1.20
Change (%) -3.42%
Day's Open 34.72
Day's Range 32.63 - 35.99
Day's Volume 149,751
52-Week Range 28.00 - 37.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

CAMBRIDGE, Mass., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Cullinan Management, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and ...

GlobeNewsWire - 1 week ago

CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Please note that the embedded hyperlinks in the press release below have been corrected from a release issued under the same headline earlie...

GlobeNewswire - 1 week ago

CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cullinan Management, Inc., a biopharmaceutical company focused on developing a diversified pipeline...

NASDAQ - 1 week ago

Cullinan Management, a Phase 1/2a biotech developing and investing in oncology therapies, raised the proposed deal size for its upcoming IPO on Wednesday.

GlobeNewswire - 3 weeks ago

- Zai Lab to lead development and commercialization of CLN-081 in Greater China - Cullinan will receive $20 million upfront, up to $211 million in...

Business Wire - 1 month ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cullinan Oncology, LLC, a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with tran...

SEC - 1 month ago

Cullinan Management, Inc. has filed to go public with an IPO on the NASDAQ.

About CGEM

Cullinan Oncology, LLC, a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. Its lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. The company's preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of soli... [Read more...]

Industry
Biotechnology
IPO Date
Jan 8, 2021
CEO
Owen Hughes
Employees
17
Stock Exchange
NASDAQ
Ticker Symbol
CGEM
Full Company Profile

Financial Performance

Financial Statements